Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

3.91
+0.16004.27%
Post-market: 3.88-0.0300-0.77%19:48 EDT
Volume:471.13K
Turnover:1.82M
Market Cap:301.52M
PE:-3.93
High:3.95
Open:3.81
Low:3.72
Close:3.75
Loading ...

Corvus Pharmaceuticals Unveils Promising Interim Results from Phase 1 Trial of Soquelitinib for Atopic Dermatitis

Reuters
·
04 Jun

Corvus Pharmaceuticals Inc - All Cohorts Show Statistically Significant Difference From Placebo at Day 28

THOMSON REUTERS
·
04 Jun

Corvus Pharmaceuticals Announces Full Data From Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

THOMSON REUTERS
·
04 Jun

Corvus Pharmaceuticals Inc - Cohort 3 Shows Earlier and Deeper Responses Compared to Cohorts 1-2

THOMSON REUTERS
·
04 Jun

Corvus Pharmaceuticals Inc - Cohort 3 Shows Clinically Meaningful Reduction in Itch by Day 8

THOMSON REUTERS
·
04 Jun

Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating

MT Newswires Live
·
20 May

Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings

TIPRANKS
·
10 May

Corvus Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
10 May

Corvus Pharmaceuticals Price Target Raised to $17.00/Share From $15.00 by Oppenheimer

Dow Jones
·
10 May

Corvus Pharmaceuticals Up Over 26%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk

Dow Jones
·
09 May

Wall Street Set to Open Higher Friday as Investors Calmed by Trade Talks

MT Newswires Live
·
09 May

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating

MT Newswires Live
·
09 May

Corvus Pharmaceuticals Shares Surge on Study Data Evaluating Soquelitinib

Dow Jones
·
09 May

US Equity Futures Higher as Trump Considers 80% China Tariffs

MT Newswires Live
·
09 May

Mizuho Securities Reaffirms Their Buy Rating on Corvus Pharmaceuticals (CRVS)

TIPRANKS
·
09 May

Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket

MT Newswires Live
·
09 May

Corvus Pharma Q1 EPS $(0.13) Misses $(0.12) Estimate

Benzinga
·
09 May

Corvus Pharmaceuticals Reports Q1 2025 Results: Net Income Surges to $15.2M, Driven by $25.1M Gain from Warrant Liability Adjustment

Reuters
·
09 May

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

THOMSON REUTERS
·
09 May

Corvus Pharmaceuticals Inc Q1 Shr View $-0.12 -- Lseg Ibes Data

THOMSON REUTERS
·
09 May